Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than
2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression …

In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

Simple Summary Glioblastoma is the most common and aggressive malignant primary brain
cancer in adults. The prognosis remains poor following standard-of-care treatment with …

Introduction Glioblastoma is a very aggressive cancer with dismal prognosis despite
standard of care including surgical resection, radiation therapy, and chemotherapy. There is …

Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light
of the multitude of recent phase III trials that have failed to meet their primary endpoints …

Opinion statement At this time, there are no FDA-approved immune therapies for
glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor
of the central nervous system and has a very poor prognosis. The current standard of care …

Over the past century, treatment of malignant tumors of the brain has remained a challenge.
Refinements in neurosurgical techniques, discovery of powerful chemotherapeutic agents …